| Full Name | Dynactin Subunit 2 (p50) |
|---|---|
| Symbol | DCTN2 |
| Chromosomal Location | 12q13.13 |
| NCBI Gene ID | 10540 |
| OMIM | 607375 |
| Ensembl | ENSG00000175224 |
| Encoded Protein | [DCTN2 Protein](/proteins/dctn2) |
| Core Complex | [Dynactin Protein](/proteins/dynactin-protein) |
DCTN2 encodes dynactin subunit 2 (historically "p50"), a core component of the dynactin complex. Dynactin cooperates with cytoplasmic dynein to support long-range minus-end-directed transport on microtubules, a process that is especially critical in neurons with long axons.[1][2] At the pathway level, dynein-dynactin transport supports retrograde signaling, organelle quality control, and autophagic cargo clearance, mechanisms repeatedly implicated in Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis.[3][4]
DCTN2 is part of the dynactin shoulder module and contributes to structural integrity needed for productive dynein activation by cargo adaptors such as BICD family proteins.[1:1][2:1] While DCTN1 (p150) provides the best-characterized microtubule-interacting and dynein-contact interfaces, DCTN2 stabilizes assembly states that allow the motor-adaptor-dynactin supercomplex to form and remain processive over long distances.[1:2][2:2]
In polarized neurons, dynein-dynactin function is required for:
When this transport axis is reduced, neurons can accumulate damaged cargoes in distal neurites and exhibit progressive stress signaling and synaptic failure, patterns broadly observed in neurodegenerative disease models.[3:2][5:1]
Direct, replicated monogenic DCTN2 causality in major adult neurodegenerative syndromes is currently weaker than evidence for DCTN1-associated disorders such as Perry syndrome.[6:1] For clinical interpretation, DCTN2 is best treated as a high-priority pathway gene with plausible contributory risk rather than a definitive stand-alone disease driver.
Transcriptomic atlases report broad DCTN2 expression, including substantial CNS expression consistent with the pervasive need for dynein-dynactin transport in neuronal maintenance.[8][9] Vulnerability is expected to be highest in large projection neurons and motor circuits where transport distance and energetic demand are extreme.
Therapeutic logic currently favors network-level rescue of axonal transport and proteostasis rather than direct inhibition of DCTN2:
Urnavicius L, et al. Cryo-EM shows how dynactin recruits two dyneins for faster movement. Nature. 2018. ↩︎ ↩︎ ↩︎ ↩︎
Schlager MA, et al. In vitro reconstitution of a highly processive recombinant human dynein complex. EMBO J. 2014. ↩︎ ↩︎ ↩︎ ↩︎
Moughamian AJ, Holzbaur ELF. Dynactin is required for transport initiation from the distal axon. Neuron. 2014. ↩︎ ↩︎ ↩︎ ↩︎
Millecamps S, Julien JP. Axonal transport deficits and neurodegenerative diseases. Nat Rev Neurosci. 2013. ↩︎ ↩︎ ↩︎ ↩︎
De Vos KJ, Grierson AJ, Ackerley S, Miller CCJ. Role of axonal transport in neurodegenerative diseases. Annu Rev Neurosci. 2008. ↩︎ ↩︎ ↩︎ ↩︎
Farrer MJ, et al. DCTN1 mutations in Perry syndrome. Nat Genet. 2009. ↩︎ ↩︎
Hoang HT, et al. Mutations in the motor domain of DYNC1H1 cause dominant spinal muscular atrophy. Ann Neurol. 2017. ↩︎
Fagerberg L, et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Syst Biol. 2014. ↩︎
Uhlen M, et al. A pathology atlas of the human cancer transcriptome. Science. 2017. ↩︎